Eli Lilly and Company
LLYNYSE
$1,294.35
Last price · USD
- Market cap
- $1.16T
- P/E
- 56.4x
- EV / EBITDA
- 37.8x
- P/S
- 17.8x
- FCF yield
- 0.8%
- Div. yield
- 0.46%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$65.18B
+44.7%
4Y CAGR +23.2%
Gross profit
$54.13B
+47.8%
4Y CAGR +26.7%
Operating income
$29.70B
+74.3%
4Y CAGR +39.1%
Net income
$20.64B
+94.9%
4Y CAGR +38.7%
EPS (diluted)
$22.95
+96.0%
4Y CAGR +40.7%
Free cash flow
$8.97B
+138.6%
4Y CAGR +13.6%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $1,294.35 · FY2025 fundamentals
- Market cap
- $1.16T
- Enterprise value
- $1.20T
- P/E
- 56.4x
- P/S
- 17.8x
- P/B
- 43.8x
- EV / EBITDA
- 37.8x
- EV / Sales
- 18.4x
- Earnings yield
- 1.8%
- FCF yield
- 0.8%
- Shareholder yield
- 0.8%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 83.0%+8.9pp | 74.2% | |
| Operating margin | 45.6%+17.5pp | 28.0% | |
| EBITDA margin | 48.6%+20.2pp | 28.4% | |
| Net margin | 31.7%+12.0pp | 19.7% | |
| FCF margin | 13.8%-5.3pp | 19.0% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 77.8% | 62.2% | |
| Return on invested capital | 38.5% | 32.6% | |
| Return on assets | 18.4% | 11.4% | |
| Debt / equity | 1.60x | 1.88x | |
| Net debt / EBITDA | 1.12x | 1.62x | |
| Current ratio | 1.58x | 1.23x |
Cash & equivalents
$7.16B
Total debt
$42.50B
Capital allocation
How LLY used its cash in FY2025
- Operating cash flow
- $16.81B
- Capital expenditure
- $7.84B
- Dividends paid
- $5.38B
- Share repurchases
- $4.11B
- Stock-based compensation
- $626M
- Diluted shares
- 898.0M
- Share count change (4Y)
- -5.8%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $65.18B | $22.95 | ||
| FY2026E15 analysts | $88.76B | +36.2% | $34.05 | +48.4% |
| FY2027E15 analysts | $102.6B | +15.6% | $47.31 | +39.0% |
| FY2028E10 analysts | $115.0B | +12.0% | $54.21 | +14.6% |
About Eli Lilly and Company
Healthcare · Drug Manufacturers - General
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.
lilly.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks
- Employees
- 50,000
- Headquarters
- Indianapolis, IN, US
- IPO date
- 1972-06-01
Eli Lilly and Company (LLY) — frequently asked questions
Answered from the company's SEC filings
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.